Modulation of RAAS-natriuretic peptides in the treatment of HF: Old guys and newcomers

International Journal of Cardiology

Volumn 226, Issue , 2017, Pages 126-131

  Mollace, Vincenzo ^a   Gliozzi, Micaela ^a   Capuano, Annalisa ^b   Rossi, Francesco ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

AT1 receptor modulators; AT2 receptor modulators; Heart failure; RAAS inhibitors; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE SYNTHASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BR 4628; CANDOXATRIL; DAGLUTRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMPATRILAT; GLUCOCORTICOID RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; OMAPATRILAT; PF 3882845; RENIN INHIBITOR; SACUBITRIL PLUS VALSARTAN; SAMPATRILAT; SLV 338; SM 368229; THIORPHAN; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; PHYSIOLOGY; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 84962715433     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.085     Document Type: Review

References (41)

1. [1] McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic Heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14:8 (Aug 2012), 803–869.
2. [2] Rossi, F., Cuomo, V., Riccardi, C., Farmacologia. Principi di base e applicazioni terapeutiche. Seconda edizione, 2011, Minerva Medica.
3. [3] Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131:4 (Jan 27 2015), e29–322.
4. [4] Reid, J.L., Present aspects and future developments with ACE inhibitors. Cardiology 76:Suppl. 2 (1989), 1–10.
5. [5] Gonzalez, G.E., Rhaleb, N.E., Nakagawa, P., Liao, T.D., Liu, Y., Leung, P., et al. N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats. Clin. Sci. (Lond.) 126:1 (Jan 1 2014), 85–94.
6. [6] Luque, M., Martin, P., Martell, N., Fernandez, C., Brosnihan, K.B., Ferrario, C.M., Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J. Hypertens. 14:6 (Jun 1996), 799–805.
7. [7] Santos, R.A., Campagnole-Santos, M.J., Andrade, S.P., Angiotensin-(1–7): an update. Regul. Pept. 91:1–3 (Jul 28 2000), 45–62.
8. [8] Dickstein, K., Kjekshus, J., Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 360:9335 (Sep 7 2002), 752–760.
9. [9] Maggioni, A.P., Anand, I., Gottlieb, S.O., Latini, R., Tognoni, G., Cohn, J.N., Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. 40:8 (Oct 16 2002), 1414–1421.
10. [10] Romero, C.A., Orias, M., Weir, M.R., Novel RAAS agonists and antagonists: clinical applications and controversies. Nat. Rev. Endocrinol. 11:4 (Apr 2015), 242–252.
11. [11] Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34:31 (Aug 2013), 2453–2463.
12. [12] Nariai, T., Fujita, K., Mori, M., Katayama, S., Hori, S., Matsui, K., SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats. J. Cardiovasc. Pharmacol. 59:5 (May 2012), 458–464.
13. [13] Meyers, M.J., Arhancet, G.B., Hockerman, S.L., Chen, X., Long, S.A., Mahoney, M.W., et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J. Med. Chem. 53:16 (Aug 26 2010), 5979–6002.
14. [14] Fagart, J., Hillisch, A., Huyet, J., Barfacker, L., Fay, M., Pleiss, U., et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J. Biol. Chem. 285:39 (Sep 24 2010), 29932–29940.
15. [15] Amar, L., Azizi, M., Menard, J., Peyrard, S., Watson, C., Plouin, P.F., Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56:5 (Nov 2010), 831–838.
16. [16] Lea, W.B., Kwak, E.S., Luther, J.M., Fowler, S.M., Wang, Z., Ma, J., et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 75:9 (May 2009), 936–944.
17. [17] Zimmer, C., Hafner, M., Zender, M., Ammann, D., Hartmann, R.W., Vock, C.A., N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2). Bioorg. Med. Chem. Lett. 21:1 (Jan 1 2011), 186–190.
18. [18] Clarke, N.E., Turner, A.J., Angiotensin-converting enzyme 2: the first decade. Int. J. Hypertens., 2012, 2012, 307315.
19. [19] Zhong, J., Basu, R., Guo, D., Chow, F.L., Byrns, S., Schuster, M., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122:7 (Aug 17 2010), 717–728 (18 p following 28).
20. [20] Rehman, A., Leibowitz, A., Yamamoto, N., Rautureau, Y., Paradis, P., Schiffrin, E.L., Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 59:2 (Feb 2012), 291–299.
21. [21] Kaschina, E., Grzesiak, A., Li, J., Foryst-Ludwig, A., Timm, M., Rompe, F., et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin–angiotensin system in myocardial infarction?. Circulation 118:24 (Dec 9 2008), 2523–2532.
22. [22] Pinheiro, S.V., AC, Simoes e Silva, WO, Sampaio, RD, de Paula, EP, Mendes, ED, Bontempo, et al. Nonpeptide AVE 0991 is an angiotensin-(1–7) receptor Mas agonist in the mouse kidney. Hypertension 44:4 (Oct 2004), 490–496.
23. [23] Wiemer, G., Dobrucki, L.W., Louka, F.R., Malinski, T., Heitsch, H., AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1–7) on the endothelium. Hypertension 40:6 (Dec 2002), 847–852.
24. [24] Bertagnolli, M., Casali, K.R., De Sousa, F.B., Rigatto, K., Becker, L., Santos, S.H., et al. An orally active angiotensin-(1–7) inclusion compound and exercise training produce similar cardiovascular effects in spontaneously hypertensive rats. Peptides 51 (Jan 2014), 65–73.
25. [25] Lee, H., Chai, S., Pong, W., Welungoda, I., Gaspari, T., AT4 receptor/insulin regulated aminopeptidase inhibition protects against angiotensin II-induced cardic fibrosis and vascular dysfunction [abstract 33.39]. J. Hypertens., 32(Suppl. 1), 2014, e551.
26. [26] Pandey, R., Quan, W.Y., Hong, F., Jie, S.L., Vaccine for hypertension: modulating the renin–angiotensin system. Int. J. Cardiol. 134:2 (May 15 2009), 160–168.
27. [27] von Lueder, T.G., Atar, D., Krum, H., Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol. Ther. 144:1 (Oct 2014), 41–49.
28. [28] Campbell, D.J., Anastasopoulos, F., Duncan, A.M., James, G.M., Kladis, A., Briscoe, T.A., Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J. Pharmacol. Exp. Ther. 287:2 (Nov 1998), 567–577.
29. [29] Kaye, D.M., Krum, H., Drug discovery for heart failure: a new era or the end of the pipeline?. Nat. Rev. Drug Discov. 6:2 (Feb 2007), 127–139.
30. [30] Martin, P., Tzanidis, A., Stein-Oakley, A., Krum, H., Effect of a highly selective endothelin-converting enzyme inhibitor on cardiac remodeling in rats after myocardial infarction. J. Cardiovasc. Pharmacol. 36:5 Suppl. 1 (Nov 2000), S367–S370.
31. [31] Volpe, M., Natriuretic peptides and cardio-renal disease. Int. J. Cardiol. 176:3 (Oct 20 2014), 630–639.
32. [32] Kostis, J.B., Packer, M., Black, H.R., Schmieder, R., Henry, D., Levy, E., Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am. J. Hypertens. 17:2 (Feb 2004), 103–111.
33. [33] Packer, M., Califf, R.M., Konstam, M.A., Krum, H., McMurray, J.J., Rouleau, J.L., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 106:8 (Aug 20 2002), 920–926.
34. [34] Fryer, R.M., Segreti, J., Banfor, P.N., Widomski, D.L., Backes, B.J., Lin, C.W., et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br. J. Pharmacol. 153:5 (Mar 2008), 947–955.
35. [35] Vardeny, O., Miller, R., Solomon, S.D., Combined neprilysin and renin–angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2:6 (Dec 2014), 663–670.
36. [36] Gu, J., Noe, A., Chandra, P., Al-Fayoumi, S., Ligueros-Saylan, M., Sarangapani, R., et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor–neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 50:4 (Apr 2010), 401–414.
37. [37] von Lueder, T.G., Wang, B.H., Kompa, A.R., Huang, L., Webb, R., Jordaan, P., et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ. Heart Fail. 8:1 (Jan 2015), 71–78.
38. [38] Kurtz, T.W., Klein, U., Next generation multifunctional angiotensin receptor blockers. Hypertens. Res. 32:10 (Oct 2009), 826–834.
39. [39] Richards, A.M., The renin–angiotensin–aldosterone system and the cardiac natriuretic peptides. Heart 76:3 Suppl. 3 (Nov 1996), 36–44.
40. [40] Deddish, P.A., Marcic, B., Jackman, H.L., Wang, H.Z., Skidgel, R.A., Erdos, E.G., N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1–7) and keto-ACE. Hypertension 31:4 (Apr 1998), 912–917.
41. [41] Pinheiro, S.V., Simoes, E.S.A.C., Angiotensin converting enzyme 2, angiotensin-(1–7), and receptor MAS axis in the kidney. Int. J. Hypertens., 2012, 2012, 414128.